From immunotoxicity to nanotherapy: the effects of nanomaterials on the immune system.
The potential for human exposure to the diverse and ever-changing world of nanoscale materials has raised concerns about their influence on health and disease. The novel physical and chemical properties of these materials, which are associated with their small size, complicate toxicological evaluations. Further, these properties may make engineered nanomaterials (ENMs) a prime target for interaction with the immune system following uptake by phagocytes. Undesired effects on antigen-presenting cells and other phagocytic cells are of concern due to the high likelihood of ENM uptake by these cells. In addition, ENM interactions with lymphocytes and other cell types can contribute to a varied spectrum of possible effects, including inflammation, hypersensitivity, and immunomodulation. Furthermore, the mast cell (a type of immune cell traditionally associated with allergy) appears to contribute to certain inflammatory and toxic effects associated with some ENMs. Although incidental exposure may be undesirable, nanomedicines engineered for various clinical applications provide opportunities to develop therapies that may or may not intentionally target the immune system. The interaction between ENMs and the immune system and the resulting pharmacokinetic and phenotypic responses are critical factors that dictate the balance between toxicity and clinical efficacy of nanotherapeutics.
['Smith|Matthew J|MJ|', 'Brown|Jared M|JM|', 'Zamboni|William C|WC|', 'Walker|Nigel J|NJ|']
D000818:Animals D004337:Drug Carriers D006801:Humans D007107:Immune System D056747:Immunomodulation D050997:Nanomedicine D049329:Nanostructures D004364:Pharmaceutical Preparations D014025:Titanium
immunotoxicity nanomaterials immune system mast cells drug carrier agents